Literature DB >> 7380913

Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.

R J Strife, I Jardine, M Colvin.   

Abstract

A rapid and convenient high-performance liquid chromatographic procedure for the analysis of the clinically useful anticancer agents VP 16-213 and VM 26 is described. The drugs, which are semi-synthetic derivatives of the natural product podophyllotoxin, are extracted from plasma with chloroform. The extracts are evaporated to dryness, reconstituted in methanol, and chromatographed on a reversed-phase microparticle C18 column using isocratic elution with a mixture of methanol--water (60:40). Each drug is used as the internal standard for the other. Quantitation to 500 ng/ml (0.85 nmole/ml) plasma is based on peak height ratios using UV detection at 254 nm. Patient plasma concentration versus time data agree well with previously published data obtained using radiolabelled drug. Investigations into the nature of the hydroxy acid metabolite of VP 16-213, carried out using paired-ion chromatography with tetrabutylammonium bromide and fluorescence detection, are described. Also, a unique separation of VP 16-213 and a possible metabolite, the isomer, picro VP 16-213, is described.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7380913     DOI: 10.1016/s0378-4347(00)81625-4

Source DB:  PubMed          Journal:  J Chromatogr


  16 in total

Review 1.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 2.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

3.  A highly sensitive enzyme-linked immunosorbent assay for etoposide using beta-D-galactosidase as a label.

Authors:  T Saita; K Fujiwara; T Kitagawa; M Mori; K Takata
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity.

Authors:  J D Loike
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide.

Authors:  J M Jones; E A Olman; M J Egorin; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.

Authors:  W E Evans; J A Sinkule; W R Crom; L Dow; A T Look; G Rivera
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  A radioimmunoassay for VP16-213 in plasma.

Authors:  G W Aherne; V Marks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Pharmacokinetics of VP16-213 given by different administration methods.

Authors:  M D'Incalci; P Farina; C Sessa; C Mangioni; V Conter; G Masera; M Rocchetti; M B Pisoni; E Piazza; M Beer; F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 10.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.